Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants

Ähnliche Einträge

• Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein Inhibition
  von: Hongxia Jia, et al.
  Veröffentlicht: (2025)
• Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants
  von: Matthias Hoch, et al.
  Veröffentlicht: (2025)
• Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study
  von: Ramesh Boinpally, et al.
  Veröffentlicht: (2024)
• A Drug‐Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2‐ and MATE1‐Mediated Transport of Metformin in Healthy Participants
  von: Rajinder Bhardwaj, et al.
  Veröffentlicht: (2024)
• Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug‐Drug Interaction of Avacopan in 2 Open‐Label Studies in Healthy Participants
  von: Shichang Miao, et al.
  Veröffentlicht: (2024)